Hormonal
GLP-1 receptor agonists (exenatide, liraglutide) are effective for weight loss in patients with schizophrenia who are gaining weight due to antipsychotic medications (clozapine/olanzapine).
For patients with schizophrenia taking clozapine or olanzapine who experience significant weight gain, GLP-1 agonists (exenatide or liraglutide) are a promising treatment option. They effectively reduce weight gain (avg 3.71 kg difference) without interacting with the antipsychotic medications, avoiding the need to change psychiatric treatment.
From the data analysis, it is concluded that the use of GLP-1 treatment for weight control in patients with schizophrenia using clozapine or olanzapine is very promising. The mean weight loss between the intervention and control groups was 3.71 kg less for the intervention groups.
Why this rating
Based on a small number of studies (3 studies cited) with varying designs (blinded, open-label).
Source
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Giulia Biagi Furlan et al. · International Journal of Nutrology · 2023
DOI 10.54448/ijn23105
More from this paper
- GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.Good
- GLP-1 receptor agonists (Liraglutide, Semaglutide) are effective and safe for treating obesity in children and adolescents, with FDA approval for Liraglutide in this population.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →